ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Time Follow-Up
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 8253" data-attributes="member: 3"><p><a href="http://www.ncbi.nlm.nih.gov/pubmed/24828032#" target="_blank">J Sex Med.</a> 2014 May 14. doi: 10.1111/jsm.12571. [Epub ahead of print]</p><p><strong>Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Time Follow-Up: Results from the European Network for the Investigation of Gender Incongruence.</strong><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Wierckx%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24828032" target="_blank">Wierckx K</a>1,</p><p></p><p>[h=3][/b]1Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.</p><p></p><p></p><p>[h=3]Abstract[/b]</p><p></p><p>[h=4]INTRODUCTION:[/b]Data on the effects of cross-sex hormone therapy (CHT) are limited due to the low prevalence of gender dysphoria, small number of subjects treated at each center, lack of prospective studies, and wide variations in treatment modalities.</p><p></p><p></p><p>[h=4]AIM:[/b]The aim of this study is to report the short-term effects of CHT on hormonal and clinical changes, side effects, and adverse events in trans men (female-to-male gender dysphoric persons) and trans women (male-to-female gender dysphoric persons).</p><p></p><p></p><p>[h=4]METHODS:[/b]This was a multicenter 1-year prospective study in 53 trans men and 53 trans women. Trans men received injections of testosterone undecanoate every 3 months. Trans women younger than 45 years received 50&#8201;mg cyproterone acetate (CA) and 4&#8201;mg estradiol valerate daily, whereas those older than 45 years received 50&#8201;mg CA daily together with 100&#8201;&#956;g/24 hours transdermal 17-&#946; estradiol.</p><p></p><p></p><p>[h=4]MAIN OUTCOME MEASURES:[/b]Sex steroids, prolactin, liver enzymes, lipids, hematocrit, blood pressure, anthropometrics, Ferriman and Gallwey score, and global acne grading scale were measured. Side effects, adverse events, and desired clinical changes were examined.</p><p></p><p></p><p>[h=4]RESULTS:[/b]No deaths or severe adverse events were observed. Two trans men developed erythrocytosis, and two had transient elevation of the liver enzymes. <strong>Trans men reported an increase in sexual desire, voice instability, and clitoral pain (all P&#8201;&#8804;&#8201;0.01). Testosterone therapy increased acne scores, facial and body hair, and prevalence of androgenetic alopecia. Waist-hip ratio, muscle mass, triglycerides, total cholesterol (C), and LDL-C increased, whereas total body fat mass and HDL-C decreased.</strong> Three trans women experienced transient elevation of liver enzymes. A significant increase in breast tenderness, hot flashes, emotionality, and low sex drive was observed (all P&#8201;&#8804;&#8201;0.02). Fasting insulin, total body fat mass, and prolactin levels increased, and waist-hip ratio, lean mass, total C, and LDL-C decreased.</p><p></p><p></p><p>[h=4]CONCLUSIONS:[/b]Current treatment modalities were effective and carried a low risk for side effects and adverse events at short-time follow-up. Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K, Kaufman JM, and T'Sjoen G. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European Network for the Investigation of Gender Incongruence.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 8253, member: 3"] [URL="http://www.ncbi.nlm.nih.gov/pubmed/24828032#"]J Sex Med.[/URL] 2014 May 14. doi: 10.1111/jsm.12571. [Epub ahead of print] [b]Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Time Follow-Up: Results from the European Network for the Investigation of Gender Incongruence.[/b][URL="http://www.ncbi.nlm.nih.gov/pubmed?term=Wierckx%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24828032"]Wierckx K[/URL]1, [h=3][/b]1Department of Endocrinology, Ghent University Hospital, Ghent, Belgium. [h=3]Abstract[/b] [h=4]INTRODUCTION:[/b]Data on the effects of cross-sex hormone therapy (CHT) are limited due to the low prevalence of gender dysphoria, small number of subjects treated at each center, lack of prospective studies, and wide variations in treatment modalities. [h=4]AIM:[/b]The aim of this study is to report the short-term effects of CHT on hormonal and clinical changes, side effects, and adverse events in trans men (female-to-male gender dysphoric persons) and trans women (male-to-female gender dysphoric persons). [h=4]METHODS:[/b]This was a multicenter 1-year prospective study in 53 trans men and 53 trans women. Trans men received injections of testosterone undecanoate every 3 months. Trans women younger than 45 years received 50 mg cyproterone acetate (CA) and 4 mg estradiol valerate daily, whereas those older than 45 years received 50 mg CA daily together with 100 μg/24 hours transdermal 17-β estradiol. [h=4]MAIN OUTCOME MEASURES:[/b]Sex steroids, prolactin, liver enzymes, lipids, hematocrit, blood pressure, anthropometrics, Ferriman and Gallwey score, and global acne grading scale were measured. Side effects, adverse events, and desired clinical changes were examined. [h=4]RESULTS:[/b]No deaths or severe adverse events were observed. Two trans men developed erythrocytosis, and two had transient elevation of the liver enzymes. [B]Trans men reported an increase in sexual desire, voice instability, and clitoral pain (all P ≤ 0.01). Testosterone therapy increased acne scores, facial and body hair, and prevalence of androgenetic alopecia. Waist-hip ratio, muscle mass, triglycerides, total cholesterol (C), and LDL-C increased, whereas total body fat mass and HDL-C decreased.[/B] Three trans women experienced transient elevation of liver enzymes. A significant increase in breast tenderness, hot flashes, emotionality, and low sex drive was observed (all P ≤ 0.02). Fasting insulin, total body fat mass, and prolactin levels increased, and waist-hip ratio, lean mass, total C, and LDL-C decreased. [h=4]CONCLUSIONS:[/b]Current treatment modalities were effective and carried a low risk for side effects and adverse events at short-time follow-up. Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K, Kaufman JM, and T'Sjoen G. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European Network for the Investigation of Gender Incongruence. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Time Follow-Up
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top